MEDI 7734

Drug Profile

MEDI 7734

Alternative Names: MEDI-7734

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SBI Biotech
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Autoimmune disorders in USA (SC) (NCT02780674)
  • 02 Jun 2016 Medimmune plans a phase I trial for Autoimmune disorders in USA and Germany (NCT02780674)
  • 01 Jun 2016 Preclinical trials in Autoimmune disorders in USA (SC) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top